Similar HRQOL With Gilteritinib vs Placebo in FLT3-ITD+ AML Post-HCT

Betty K. Hamilton, MD, associate professor of medicine at the Cleveland Clinic, discusses findings from a study comparing gilteritinib (Xospata) vs placebo post-allogeneic hematopoietic cell transplantation (HCT) for the treatment of patient with FLT3-ITD-positive acute myeloid leukemia (AML)

An exploratory analysis on health-related quality of life (HRQOL) using FACT-bone marrow transplant (BMT), FACT-Leukemia, and EQ-5D-5L measures found there to be no significant differences between patients treated with gilteritinib and placebo. Both arms showed improvements post-HCT. While there were more TEAEs with gilteritinib, patient-reported tolerability remained similar between groups.

Transcription:

0:09 | We found no significant differences in quality-of-life between patients receiving gilteritinib vs placebo. There we used several health-related quality-of-life measures, including the FACT-BMT, the FACT-Leukemia, and the EQ-5D-5L, which was an international health-related quality-of-life measure. Across all domains, there were no significant differences in quality-of-life between patients who received gilteritinib vs placebo. We did find that health-related quality-of-life did improve over time post transplant, [which was] consistent with other studies. Specifically, there was a question that was investigated that evaluated treatment tolerability, whether a patient was bothered by [adverse] effects, and there was no difference in responses to that either between gilteritinib and placebo.

1:08 | In the transplant population, this is a cohort that is often cared for and followed by a transplant center, however, again, it is important to note that getting the patient's perspective and patient-reported outcomes and quality-of-life is really important. [For] these maintenance therapies, there [are] increasing data to support their use, and can not only improve survival, but also shows that it is well-tolerated.

REFERENCE:

Hamilton BK, Levis MJ, Pandya BJ, et al. Health-related quality of life with gilteritinib versus placebo post-transplant maintenance for FLT3-ITD+ acute myeloid leukemia (AML): a quality of life analysis from BMT CTN 1506. Presented at: 2024 Transplantation & Cellular Therapy Meetings; February 21-24, 2024; San Antonio, TX. Abstract 51.